Preclinical evaluation of 1H-benzylindole derivatives as novel human immunodeficiency virus integrase strand transfer inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 8, 2008, Pages 2861-2869

  Hombrouck, Anneleen ^a   Van Remoortel, Barbara ^a   Michiels, Martine ^a   Noppe, Wim ^a   Christ, Frauke ^a   Eneroth, Anders ^b   Sahlberg, Britt Louise ^b   Benkestock, Kurt ^b   Vrang, Lotta ^b   Johansson, Nils Gunnar ^b   Barreca, Maria Letizia ^c,d   De Luca, Laura ^c   Ferro, Stefania ^c   Chimirri, Alba ^c   Debyser, Zeger ^a   Witvrouw, Myriam ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MEDIVIR AB   (Sweden)

^c UNIVERSITY OF MESSINA   (Italy)

^d UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; AZATHIOPRINE; CHI 1013; CHI 1014; CHI 1037; CHI 1038; CHI 1042; CHI 1043; CHI 1047; CHI 1089; CHI 1096; CHI 1133; CHI 1202; CHI 1203; EFAVIRENZ; ELVITEGRAVIR; INDOLE DERIVATIVE; INTEGRASE INHIBITOR; L 708906; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; NELFINAVIR; OLIGONUCLEOTIDE; PROTEINASE INHIBITOR; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL LINE; CONCENTRATION RESPONSE; CYTOTOXICITY; DNA INTEGRATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG TRANSPORT; ENZYME ASSAY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; LIVER MICROSOME; MOLECULAR MODEL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; QUANTITATIVE ANALYSIS; SIMIAN IMMUNODEFICIENCY VIRUS; STRUCTURE ACTIVITY RELATION; VIRUS DNA CELL DNA INTERACTION; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS STRAIN;

ANTI-HIV AGENTS; CACO-2 CELLS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV; HIV INTEGRASE INHIBITORS; HUMANS; INDOLES; INTEGRASES; MOLECULAR STRUCTURE; POLYMERASE CHAIN REACTION; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 48749084101     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00210-08     Document Type: Article

References (43)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Artursson, P., and J. Karlsson. 1991. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175:880-885.
3. Barreca, M. L., S. Ferro, A. Rao, L. De Luca, M. Zappala, A. M. Monforte, Z. Debyser, M. Witvrouw, and A. Chimirri. 2005. Pharmacophore-based design of HIV-1 integrase strand-transfer inhibitors. J. Med. Chem. 48:7084-7088.
4. Barré-Sinoussi, F., J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Vezinet-Brun, C. Rouzioux, W. Rozenbaum, and L. Montagnier. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868-871.
5. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, et al. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
6. Cooper, D., J. Gatell, J. Rockstroh, C. Katlama, P. Yeni, A. Lazzarin. J. Chen, R. Isaacs, H. Teppler, and B. Nguyen. 2007. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple class resistant virus, abstr. 105aLB, p. 103. Abstr. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
7. Daniel, M. D., N. L. Letvin, P. K. Sehgal, G. Hunsmann, D. K. Schmidt, N. W. King, and R. C. Desrosiers. 1987. Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus. I. Gen. Virol. 68:3183-3189.
8. Dayam, R., R. Gundla, L. Q. Al-Mawsawi, and N. Neamati. 2008. HIV-1 integrase inhibitors: 2005-2006 update. Med. Res. Rev. 28:118-154.
9. De Luca, L., G. Vistoli, A. Pedretti, M. L. Barreca, and A. Chimirri. 2005. Molecular dynamics studies of the full-length integrase-DNA complex. Biochem. Biophys. Res. Commun. 336:1010-1016.
10. De Luca, L., M. L. Barreca, S. Ferro, N. Iraci, M. Michiels, F. Christ, Z. Debyser, M. Witvrouw, and A. Chimirri. 2008. A refined pharmacophore model for HIV-1 integrase inhibitors: optimization of potency in the 1H-benzylindole series. Bioorg. Med. Chem. Lett. 18:2891-2895.
11. Esposito, D., Craigie. 1999. HIV integrase structure and function. Adv. Virus Res. 52:319-333.
12. Esté, J. A., C. Cabrera, D. Schols, P. Cherepanov, A. Gutierrez, M. Witvrouw, C. Pannecouque, Z. Debyser, R. F. Rando, B. Clotet, J. Desmyter, and E. De Clercq. 1998. Human immunodeficiency virus glycoprotein gpl20 as the primary target for the antiviral action of AR177 (Zintevir). Mol. Pharmacol. 53:340-345.
13. Fikkert, V., A. Hombrouck, B. Van Remoortel, M. De Maeyer, C. Pannecouque, E. De Clercq, Z. Debyser, and M. Witvrouw. 2004. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 18:2019-2028.
14. Fikkert, V., B. Van Maele, J. Vercammen, A. Hantson, B. Van Remoortel, M. Michiels, C. Gurnari, C. Pannecouque, M. De Maeyer, Y. Engelborghs, E. De Clercq, Z. Debyser, and M. Witvrouw. 2003. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J. Virol. 77:11459-11470.
15. Hara, H., T. Fujibashi, T. Sakata, A. aJi, and H. Kaji. 1997. Tetrahydronaphthalene lignan compounds as potent anti-HIV type 1 agents. AIDS Res. Hum. Retrovir. 13:695-705.
16. Hazuda, D. J., N. J. Anthony, R. P. Gomez, S. M. Jolly J. S. Wai, L. Zhuang, T. E. Fisher, M. Embrey, J. P. Guare, Jr., M. S. Egbertson, J. P. Vacca, J. R. Huff, P. J. Felock, M. V. Witmer, K. A. Stillmock, R. Danovich, J. Grobler, M. D. Miller, A. S. Espeseth, L. Jin, I. W. Chen, J. H. Lin, K. Kassahun, J. D. Ellis, B. K. Wong, W. Xu, P. G. Pearson, W. A. Schleif, R. Cortese, E. Emini, V. Summa, M. K. Holloway, and S. D. Young. 2004. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. USA 101:11233-11238.
17. Hazuda, D. J., P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J. A. Grobler, A. Espeseth, L. Gabryelski, W. Schleif, C. Blau, and M. D. Miller. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650.
18. Hazuda, D. J., M. D. Miller, B. Y. Nguyen, and J. Zhao. 2007. Resistance to the HIV-integrase inhibitor raltegravir: analysis of protocol 005, a phase 2 study in patients with triple-class resistant HIV-1 infection. Antivir. Ther. 12:S10.
19. Hombrouck, A., A. Hantson, B. Van Remoortel, M. Michiels, J. Vercammen, D. Rhodes, V. Tetz, Y. Engelborghs, F. Christ, Z. Debyser, and M. Witvrouw. 2007. Selection of human immunodeficiency virus type 1 resistance against the pyranodipyrimidine V-165 points to a multimodal mechanism of action. J. Antimicrob. Chemother. 59:1084-1095. doi:10.1093/jac/dkm101.
20. Hombrouck, A., A. Voet, B. Van Remoortel, C. Desadeleer, M. De Maeyer, Z. Debyser, and M. Witvrouw. 2008. Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Antimicrob. Agents Chemother. 52:2069-2078.
21. Horwitz, J. P., J. Chua, and M. Noel. 1964. Nucleosides. V. The monomesylates of 1-(2′-deoxy-β-D-lyxofuranosyl) thymine. J. Org. Chem. 29:2076-2078.
22. Hwang, Y., D. Rhodes, and F. Bushman. 2000. Rapid microtiter assays for poxvirus topoisomerase, mammalian type IB topoisomerase and HIV-1 integrase: application to inhibitor isolation. Nucleic Acids Res. 28:4884-4892.
23. Jones, G., R. Ledford, F. Yu, M. Miller, M. Tsiang, and D. McColl. 2007. Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303), abstr. 627. Abstr. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
24. Junker, U., J. Baker, C. S. Kalfoglou, G. Veres, H. Kaneshima, and E. Bohnlein. 1997. Antiviral potency of drug-gene therapy combinations against human immunodeficiency virus type 1. AIDS Res. Hum. Retrovir. 13:1395-1402.
25. Kelly, C. 2007. FDA approves new HIV drug. Raltegravir tablets used in combination with other antiretroviral agents. FDA, Washington, DC. www .fda.gov/bbs/topics/NEWS/2007/NEW01726.html.
26. Kirsch, R. D., and E. Joly. 1998. An improved PCR-mutagenesis strategy for two-site mutagenesis or sequence swapping between related genes. Nucleic Acids Res. 26:1848-1850.
27. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
28. Mainprize, T., and L. T. Grady. 1998. Standardization of an in vitro method of drug absorption. Pharmacopeial Forum 24:6015.
29. McColl, D., S. Fransen, and S. Gupta. 2007. Resistance and cross-resistance to first generation integrase inhibitors: insights from a phase II study of elvetigravir (GS-9137). Antivir. Ther. 12:S11.
30. Miyoshi, L., H. Taguchi, I. Kubonishi, S. Yoshimoto, Y. Ohtsuki, Y. Shiraishi, and T. Akagi. 1982. Type C virus-producing cell lines derived from adult T cell leukemia. Gann Monogr. 28:219-228.
31. Nunberg, J. H., W. A. Schleif, E. J. Boots, J. A. O'Brien, J. C. Quintero, J. M. Hoffman, E. A. Emini, and M. E. Goldman. 1991. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J. Virol. 65:4887-4892.
32. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20:309-321.
33. Pluymers, W., N. Neamati, C. Pannecouque, V. Fikkert, C. Marchand, T. R. Burke, Jr., Y. Pommier, D. Schols, E. De Clercq, Z. Debyser, and M. Witvrouw. 2000. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol. Pharmacol. 58:641-648.
34. Pommier, Y., C. Marchand, and N. Neamati. 2000. Retroviral integrase inhibitors year 2000: update and perspectives. Antivir. Res. 47:139-148.
35. Popovic, M., M. G. Sarngadharan, E. Read, and R. C. Gallo. 1984. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497-500.
36. Rey, M. A., B. Krust, A. G. Laurent, D. Guetard, L. Montagnier, and A. G. Hovanessian. 1989. Characterization of an HIV-2-related virus with a smaller sized extracellular envelope glycoprotein. Virology 173:258-267.
37. Steigbigel, R., P. Kumar, J. Eron, M. Schechter, M. Markowitz, M. Loutfy, J. Zhao, R. Isaacs, B. Nguyen, and H. Teppler. 2007. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple class resistant virus, abstr. 105bLB, p. 104. Abstr. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
38. Van Maele, B., J. De Rijck, E. De Clercq, and Z. Debyser. 2003. Impact of the central polypurine tract on the kinetics of human immunodeficiency virus type 1 vector transduction. J. Virol. 77:4685-4694.
39. Wai, J., T. Fisher, M. Embrey, M. Egbertson, J. Vacca, et al. 2007. Next generation of inhibitors of HIV-1 integrase strand transfer inhibitor: structural diversity and resistance profiles, abstr. 87, p. 96. Abstr. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.
40. Witvrouw, M., B. Van Maele, J. Vercammen, A. Hantson, Y. Engelborghs, E. De Clercq, C. Pannecouque, and Z. Debyser. 2004. Novel inhibitors of HIV-1 integration. Curr. Drug Metab. 5:291-304.
41. Young, S. D. 2001. Inhibition of HIV-1 integrase by small molecules: the potential for a new class of AIDS chemotherapeutics. Curr. Opin. Drug Discov. Dev. 4:402-410.
42. Zhuang, L., J. S. Wai, M. W. Embrey, T. E. Fisher, M. S. Egbertson, L. S. Payne, J. P. Guare, Jr., J. P. Vacca, D. J. Hazuda, P. J. Felock, A. L. Wolfe, K. A. Stillmock, M. V. Witmer, G. Moyer, W. A. Schleif, L. J. Gabryelski, Y. M. Leonard, J. J. Lynch, Jr., S. R. Michelson, and S. D. Young. 2003. Design and synthesis of 8-hydroxy-[1,6]naphthyridines as novel inhibitors of HIV-1 integrase in vitro and in infected cells. J. Med. Chem. 46:453-456.
43. Zolopa, A. 2007. The HIV integrase inhibitor GS-9137 demonstrates potent ARV activity in treatment-experienced patient, abstr. 143LB, p. 119. Abstr. 14th Conf. Retrovir. Opportunistic Infect., Los Angeles, CA.